ReviewRSC medicinal chemistry2026
Peptides as multifunctional linchpins in targeted drug conjugates.
Review in RSC medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide-drug conjugates (PDCs) represent an emerging class of targeted therapeutics engineered to enhance drug specificity and minimize systemic toxicity, showing significant promise for treating complex diseases. The peptide component is central to this strategy, fulfilling multiple critical roles. Primarily, it acts as a high-affinity homing device, selectively directing the conjugate to receptors overexpressed on target cells to minimize off-target effects. Beyond targeting, peptides are also being innovatively engineered as enzymatically cleavable linkers to enable selective drug release within a specific pathological microenvironment. Despite this potential, the clinical translation of PDCs is hindered by challenges including instability in circulation, limited tissue penetration, and insufficient targeting selectivity. This review discusses strategic advances in peptide discovery, modification, and optimization to overcome these barriers. We further provide future perspectives on constructing next-generation PDCs, underscoring their potential as highly effective precision medicines.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.